Liver transplantation for unresectable epithelioid hemangioendothelioma resulted in a projected 5-year actuarial survival rate of 76%, even in the presence of metastatic disease.
Observational (n=10)
Does liver transplantation improve survival in patients with unresectable epithelioid hemangioendothelioma?
Liver transplantation is a reasonable procedure for bulky, unresectable epithelioid hemangioendothelioma, even in the presence of metastatic disease.
Ten patients received liver transplants for unresectable epithelioid hemangioendothelioma (EHE). At the time of transplantation, four patients had microscopic metastases to the hilar lymph nodes, and one of the four also had metastases to a rib. The fifth patient had metastases to the lung, pleura, and diaphragm. The remaining five patients were believed to be free of metastatic disease. Two of these five patients died of metastatic disease at 3 and 16 months, respectively, after transplantation. Interestingly, all five patients with metastatic involvement are currently alive 40.6 +/- 22 months (mean +/- standard error of mean SEM) after transplantation, although one of these patients currently has metastatic disease to the lungs and mediastinum. Thus, the projected 5-year actuarial survival rate is 76%, with two patients at risk after the third year. In conclusion, liver transplantation is a reasonable procedure for bulky, otherwise unresectable, EHE even in the presence of metastatic disease.
Marino et al. (Tue,) conducted a observational in Unresectable epithelioid hemangioendothelioma (EHE) (n=10). Liver transplantation was evaluated on Projected 5-year actuarial survival rate. Liver transplantation for unresectable epithelioid hemangioendothelioma resulted in a projected 5-year actuarial survival rate of 76%, even in the presence of metastatic disease.